hyaluronidase (bovine)
Trade name: Wydase
Approved
Mar 22, 1950
Hyaluronidases are a family of enzymes that catalyse the degradation of hyaluronic acid. Karl Meyer classified these enzymes in 1971, into three distinct groups, a scheme based on the enzyme reaction products. The three main types of hyaluronidases are two classes of eukaryotic endoglycosidase hydrolases and a prokaryotic lyase-type of glycosidase. — Wikipedia
Clinical trial activity
16 trials · 18 clinical orgs · 8 marketing orgs
Earliest trial started Sep 1, 1977 (NCT00000493)
Timeline
1950s
- Mar 22, 1950
American Home Products — Earliest FDA Approval
- Mar 22, 1950
American Home Products — NDA Organization
- Mar 22, 1950
Baxalta — Marketing Organization
- Mar 22, 1950
Baxter — NDA Secondary Org
1970s
- Jan 1, 1977
Earliest Phase 3 Sponsor(trial)
2000s
- May 5, 2004
Bausch & Lomb — Marketing Organization
- Oct 26, 2004
Amphastar Pharmaceuticals — NDA Secondary Org
- Oct 25, 2005
Akorn, Inc. — NDA Secondary Org
- Dec 2, 2005
Halozyme Therapeutics — NDA Secondary Org
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2012
Amphastar Pharmaceuticals — Earliest Phase 2 Sponsor(trial)
2020s
- Dec 27, 2024
Bristol-Myers Squibb — Marketing Organization
Indications
Approved for
Studied for
- Arrhythmias, Cardiac · Phase 4
- Cardiovascular Diseases · Phase 3
- Chronic Pain · Early Phase 1
- Coronary Disease · Phase 3
- COVID-19 · Phase 3
- Dermatology · Phase 2
- Diabetes Mellitus, Type 1 · Early Phase 1
- Fibrosis · Phase 3
- General Surgery · Phase 2/Phase 3
- Heart Diseases · Phase 3
- Lung Diseases · Phase 3
- Lung Diseases, Interstitial · Phase 3
- Multiple Myeloma · Early Phase 1
- Myocardial Infarction · Phase 3
- Myocardial Ischemia · Phase 3
- Neuralgia · Early Phase 1
- Pharmacological and Toxicological Phenomena · Early Phase 1
- Polymyositis · Phase 3
- Renal Insufficiency · Early Phase 1
- Vaginosis, Bacterial · Phase 4
Mechanism of action
- Hyaluronic acidSupplementation
Hyaluronic acid supplementation
Combination products
opdivo qvantig
with nivolumab
Approval history
- approvedMar 22, 1950
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaHyaluronidase ↗
- ChEMBLCHEMBL2108607 ↗
- ChEMBLCHEMBL1201636 ↗
Also known as
- amphadase
- diffusin
- enzodase
- hyal-1
- hyalase
- hyaluronidase
- hyaluronidase
- hyaluronidase
- hyaluronidase
- hyaluronidase
- hyaluronidase
- hyaluronidase
- hyaluronidase
- hyaluronidase
- hyaluronidase bovine
- hyaluronidase (glycoprotein, sheep testis isoenzyme)
- hyaluronidase ovine
- hyaluronidase (ovine)
- hyaluronidase (ovine)
- hyaluronidase, ovine
- hyaluronidase ph-20
- hyaluronidase (sheep testis isoenzyme)
- hyazyme
- hydase
- hyo6a
- jalovis
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07000058 | Phase 2/Phase 3 (Phase 3) | Jun 20, 2025 | Misr University for Science and Technology |
| NCT06458543 | Phase 4 | Jun 1, 2024 | I.M. Sechenov First Moscow State Medical University |
| NCT06142396 | Early Phase 1 (Phase 1) | Jan 1, 2024 | Augusta University, Janssen Pharmaceutica NV |
| NCT06568718 | N/A | Mar 20, 2023 | NPO Petrovax Pharm LLC |
| NCT06383819 | Phase 3 | Apr 8, 2022 | I.M. Sechenov First Moscow State Medical University, NPO Petrovax Pharm LLC |
| NCT05280223 | N/A | Apr 1, 2022 | Assiut University |
| NCT05370963 | Early Phase 1 (Phase 1) | Jan 20, 2022 | Minia University |
| NCT05344495 | Early Phase 1 (Phase 1) | Jan 10, 2022 | Minia University |
| NCT03394131 | N/A | Jul 1, 2017 | Assiut University |
| NCT03675295 | N/A | Apr 2, 2017 | Assiut University |
| NCT03101033 | N/A | May 1, 2015 | People's Liberation Army of China, Xijing Hospital |
| NCT01945099 | Early Phase 1 (Phase 1) | Sep 1, 2013 | Yale University |
| NCT01722916 | Early Phase 1 (Phase 1) | Oct 1, 2012 | Northwestern University |
| NCT01689363 | Phase 2 | Sep 1, 2012 | Amphastar Pharmaceuticals |
| NCT01719978 | Phase 4 | Oct 1, 2007 | FMUSP, University of Sao Paulo |
| NCT00000493 | Phase 3 | Sep 1, 1977 | Harvard University, National Heart, Lung, and Blood Institute (NHLBI), The University of Texas, Dallas, Washington University in St. Louis |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assiut University | Academic/Hospital | 3 | 3 | 1 | 2017 |
| I.M. Sechenov First Moscow State Medical University | Academic/Hospital | 2 | 1 | 2 | 2022 |
| Minia University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| NPO Petrovax Pharm LLC | For profit | 2 | 2 | 2 | 2022 |
| Amphastar Pharmaceuticals | For profit | 1 | 1 | 1 | 2012 |
| Augusta University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| FMUSP | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 1977 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2024 |
| Misr University for Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 1 | 1 | 1977 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2015 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 1977 |
| University of Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 1977 |
| Xijing Hospital | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2013 |
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | NDA2 | Oct 25, 2005 |
| American Home Products | For profit | NDA | Mar 22, 1950 |
| Amphastar Pharmaceuticals | For profit | NDA2 | Oct 26, 2004 |
| Bausch & Lomb | For profit | MKTG | May 5, 2004 |
| Baxalta | For profit | MKTG | Mar 22, 1950 |
| Baxter | For profit | NDA2 | Mar 22, 1950 |
| Bristol-Myers Squibb | For profit | MKTG | Dec 27, 2024 |
| Halozyme Therapeutics | For profit | NDA2 | Dec 2, 2005 |